NCT03814200View on ClinicalTrials.gov

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

February 12, 2019

Study Completion Date

February 19, 2019

Conditions
Healthy Subject
Interventions
DRUG

Saline

Single i.v. infusion of 100 mL saline 0.9% for 30 min

DRUG

ACT-246475

Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions

DRUG

Rifampicin

Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min

Trial Locations (1)

9700

QPS Netherlands B.V., Groningen

All Listed Sponsors
lead

Viatris Innovation GmbH

INDUSTRY

NCT03814200 - A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects | Biotech Hunter | Biotech Hunter